Cabaletta Bio , co-founded by Penn Medicine’s Michael C. Milone, MD, PhD, Associate Professor of Pathology and Laboratory Medicine and Aimee Payne, Adjunct Professor of Dermatology, achieved FDA clearance for their fourth Investigational New Drug (IND) application for CABA-201, a CAR T cell investigational therapy. In addition to systemic lupus erythematosus, myositis, systemic sclerosis, CAB-201 is being developed to treat patients with generalized myasthenia gravis (gMG), a rare autoimmune disease characterized by profound muscle weakness, disabling fatigue, shortness of breath and risk of respiratory failure.
“Despite recent advances with chronic, broadly immunosuppressive therapies, we believe there is an unmet need for a treatment option like CABA-201 that may provide a deep and durable, perhaps curative, outcome with a single dose in patients with gMG,” said Steven Nichtberger, MD, Chief Executive Officer and co-founder of Cabaletta, as per newsite MyChesCo. The company plans to initiate a Phase 1/2 clinical trial of CABA-201 in two cohorts of patients gMG. Read more here.